神经外科切除脑转移瘤术后术中放疗作为机构标准治疗-单中心队列 117 例后肿瘤学结果的更新。
Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment- update of the oncological outcome form a single center cohort after 117 procedures.
机构信息
Department of Radiotherapy and Radio- Oncology, University Medical Center Augsburg, Augsburg, Germany.
Department of Neurosurgery, University Medical Center Augsburg, Augsburg, Germany.
出版信息
J Neurooncol. 2024 Aug;169(1):187-193. doi: 10.1007/s11060-024-04691-6. Epub 2024 Jul 4.
PURPOSE
Stereotactic radiotherapy (SRT) is the predominant method for the irradiation of resection cavities after resection of brain metastases (BM). Intraoperative radiotherapy (IORT) with 50 kV x-rays is an alternative way to irradiate the resection cavity focally. We have already reported the outcome of our first 40 IORT patients treated until 2020. Since then, IORT has become the predominant cavity treatment in our center due to patients´ choice.
METHODS
We retrospectively analyzed the outcomes of all patients who underwent resection of BM and IORT between 2013 and August 2023 at Augsburg University Medical Center (UKA).
RESULTS
We identified 105 patients with 117 resected BM treated with 50 kV x-ray IORT. Median diameter of the resected metastases was 3.1 cm (range 1.3 - 7.0 cm). Median applied dose was 20 Gy. All patients received standardized follow-up (FU) including three-monthly MRI of the brain. Mean FU was 14 months, with a median MRI FU for patients alive of nine months. Median overall survival (OS) of all treated patients was 18.2 months (estimated 1-year OS 57.7%). The observed local control (LC) rate of the resection cavity was 90.5% (estimated 1-year LC 84.2%). Distant brain control (DC) was 61.9% (estimated 1-year DC 47.9%). Only 16.2% of all patients needed WBI in the further course of disease. The observed radio necrosis rate was 2.6%.
CONCLUSION
After 117 procedures IORT still appears to be a safe and appealing way to perform cavity RT after neurosurgical resection of BM with low toxicity and excellent LC.
目的
立体定向放射治疗(SRT)是脑转移瘤(BM)切除后照射切除腔的主要方法。50kV X 射线术中放疗(IORT)是聚焦照射切除腔的另一种方法。我们已经报告了我们前 40 名接受 IORT 治疗的患者的结果,这些患者的治疗时间截至 2020 年。从那时起,由于患者的选择,IORT 已成为我们中心主要的腔治疗方法。
方法
我们回顾性分析了 2013 年至 2023 年 8 月在奥格斯堡大学医学中心(UKA)接受 BM 切除和 IORT 的所有患者的结果。
结果
我们确定了 105 名接受 50kV X 射线 IORT 治疗的 117 个切除 BM 的患者。切除转移瘤的直径中位数为 3.1cm(范围 1.3-7.0cm)。中位数应用剂量为 20Gy。所有患者均接受标准化随访(FU),包括每三个月进行一次脑部 MRI。平均 FU 为 14 个月,存活患者的中位数 MRI FU 为九个月。所有治疗患者的中位总生存期(OS)为 18.2 个月(估计 1 年 OS 为 57.7%)。切除腔的观察局部控制(LC)率为 90.5%(估计 1 年 LC 为 84.2%)。远处脑控制(DC)为 61.9%(估计 1 年 DC 为 47.9%)。只有 16.2%的患者在疾病的进一步过程中需要 WBI。观察到的放射性坏死率为 2.6%。
结论
在 117 例手术后,IORT 仍然是一种安全且有吸引力的方法,可对 BM 神经外科切除后进行腔 RT,具有低毒性和出色的 LC。